SVRA
Closed
Savara Inc
2.05
-0.23 (-10.09%)
Last Update: 01 Jul 2025 23:12:00
Yesterday: 2.28
Day's Range: 1.98 - 2.26
Send
sign up or login to leave a comment!
When Written:
1.72
Savara Inc. is a biopharmaceutical company that focuses on developing innovative therapies for rare respiratory diseases. The company was founded in 2007 and is headquartered in Austin, Texas, with additional offices in Durham, North Carolina, and Dublin, Ireland.
Savara's lead product candidate is Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) that is being developed for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). aPAP is a rare lung disease characterized by the accumulation of surfactant in the lungs, which can lead to respiratory failure.
In addition to Molgradex, Savara is also developing other product candidates for rare respiratory diseases, including AeroVanc, an inhaled antibiotic for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infections in cystic fibrosis patients, and Molgradex for nontuberculous mycobacterial (NTM) lung infections.
Savara has partnerships with several organizations, including the Cystic Fibrosis Foundation, the National Institutes of Health, and the European Union's Horizon 2020 program. The company is publicly traded on the Nasdaq stock exchange under the ticker symbol "SVRA."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Savara's lead product candidate is Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) that is being developed for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). aPAP is a rare lung disease characterized by the accumulation of surfactant in the lungs, which can lead to respiratory failure.
In addition to Molgradex, Savara is also developing other product candidates for rare respiratory diseases, including AeroVanc, an inhaled antibiotic for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infections in cystic fibrosis patients, and Molgradex for nontuberculous mycobacterial (NTM) lung infections.
Savara has partnerships with several organizations, including the Cystic Fibrosis Foundation, the National Institutes of Health, and the European Union's Horizon 2020 program. The company is publicly traded on the Nasdaq stock exchange under the ticker symbol "SVRA."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!